J.P. Morgan analyst Chris Schott maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,100.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chris Schott has given his Buy rating due to a combination of factors including the strong performance and growth potential of Eli Lilly & Co’s key products, particularly Mounjaro and Zepbound. These products have shown significant momentum in the market, with Mounjaro gaining traction internationally and Zepbound capturing a substantial share of the obesity market. Schott anticipates further growth driven by the upcoming launch of orforglipron, which is expected to contribute positively to the company’s portfolio.
Additionally, Eli Lilly’s financial outlook appears robust, with sales and earnings per share projected to grow steadily. The company’s strategic positioning and limited exposure to loss of exclusivity risks over the next decade make it an attractive investment. Schott also highlights the current valuation of Eli Lilly’s shares as an appealing entry point, given the company’s potential for sustained growth in both revenue and earnings through the early 2030s.
Schott covers the Healthcare sector, focusing on stocks such as Regeneron, Eli Lilly & Co, and Pfizer. According to TipRanks, Schott has an average return of 1.2% and a 49.84% success rate on recommended stocks.
In another report released on June 27, UBS also reiterated a Buy rating on the stock with a $1,050.00 price target.